Akaal Pharma Receives Approval to Initiate Phase 2 Clinical Trial for the Topical Treatment of Psoriasis

Autor: Akaal Pharma Pty Ltd
Zdroj: Business Wire (English). 06/16/2015.
Abstrakt: Akaal Pharma Pty Ltd, (Akaal Pharma), a clinical-stage biopharmaceutical company today announced the approval to initiate a randomized, double-blind, placebo-controlled Phase-2 clinical trial of its topical drug candidate AKP-11. AKP-11 is a novel First-in-Class topical Sphingosine 1-Phosphate receptor-1 (S1P1) modulator for the treatment of mild-to-moderate plaque psoriasis in patients. Patients will be treated daily for six weeks with the topical drug AKP-11. [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje